Recombinant Human IL5RA, Fc-tagged

• Cat.No.: IL5RA-28136TH
• Product Overview: Recombinant fragment, corresponding to amino acids 1-327 of Human IL5RA fused to the Fc region of Human IgG1 (aa 93-330 expressed in modified Human 293 cells.

Specification

• Description: The protein encoded by this gene is an interleukin 5 specific subunit of a heterodimeric cytokine receptor. The receptor is comprised of a ligand specific alpha subunit and a signal transducing beta subunit shared by the receptors for interleukin 3 (IL3), colony stimulating factor 2 (CSF2/GM-CSF), and interleukin 5 (IL5). The binding of this protein to IL5 depends on the beta subunit. The beta subunit is activated by the ligand binding, and is required for the biological activities of IL5. This protein has been found to interact with syndecan binding protein (syntenin), which is required for IL5 mediated activation of the transcription factor SOX4. Several alternatively spliced transcript variants encoding four distinct isoforms have been reported.
• Conjugation: Fc
• Form: Lyophilised:It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial.Following reconstitution short-term storage at 4°C is recommended, and longer-term storage of aliquots at -18 to -20°C. Repeated freeze thawing is not reco
• Purity: >95% by SDS-PAGE
• Storage buffer: Preservative: NoneConstituents: 10% Trehalose, 1% Human serum albumin, PBS
• Storage: Store at +4°C.
• Sequences of amino acids: Theoretical Sequence:DLLPDEKISLLPPVNFTIKVTGLAQ VLLQ WKPNPDQEQRNVNLEYQVKINAPKE DDYETRITESKCVTILHKGFSASVR TILQNDHSLLASSWASAELHAPPGS PGT SIVNLTCTTNTTEDNYSRLRSYQVS LHCTWLVGTDAPE DTQYFLYYRYGSWTEECQEYSKDTL GRNIACWFPRTFILS KGRDWLAVLVNGSSKHSAIRPFDQL FALHAIDQINPPL NVTAEIEGTRLSIQWEKPVSAFPIH CFDYEVKIHNTRNGY LQIEKLMTNAFISIIDDLSKYDVQV RAAVSSMCREAGL WSEWSQRIPKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKF NWY VDGVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNG KEYKCRVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHN HYTQKSLSLSPGK

Gene Information

• Gene Name: IL5RA interleukin 5 receptor, alpha [ Homo sapiens ]
• Official Symbol: IL5RA
• Synonyms: IL5RA; interleukin 5 receptor, alpha; IL5R; interleukin-5 receptor subunit alpha; CD125; CDw125
• Gene ID: 3568
• mRNA Refseq: NM_000564
• Protein Refseq: NP_000555
• MIM: 147851
• Uniprot ID: Q01344
• Chromosome Location: 3p26-p24
• Pathway: Cytokine Signaling in Immune system, organism-specific biosystem; Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; Hematopoietic cell lineage, organism-specific biosystem; Hematopoietic cell lineage, conserved biosystem
• Function: interleukin-5 receptor activity; protein binding; receptor activity

Reviews

04/05/2021

Good stability under different temperature and humidity conditions.

03/27/2021

In the process of purification, the removal of impurities is good.

11/13/2020

Chemical modifications, such as PEGylation or glycosylation, have little effect.

Q&As

What are the clinical applications of IL5RA?

Recombinant IL5RA can be used to treat IL5-related diseases, such as severe asthma and eosinophilic diseases. It can reduce the frequency and severity of asthma attacks by blocking the signaling of interleukin 5.

Can recombinant IL5RA be used to treat other diseases?

Currently, recombinant IL5RA is mainly used to treat IL5-related diseases, such as severe asthma and eosinophilic diseases. For other diseases, the suitability of IL5RA is subject to further research and clinical trials.

Does the use of IL5RA require blood routine examination?

During the use of IL5RA, the doctor may ask to check the patient's blood routine regularly to monitor changes in blood counts and related indicators. This helps to evaluate the efficacy of the treatment and the safety of the patient.

Does IL5RA cause dependence?

There is no clear evidence that long-term use of recombinant IL5RA causes dependence. For patients using IL5RA, it is best to treat and discontinue the drug according to the advice and guidance of their doctor.

What is the use of IL5RA?

IL5RA is generally administered by subcutaneous injection. The specific use method and dosage should be determined according to the doctor's recommendation and the specific situation of the patient.

What are the side effects of IL5RA?

Common side effects of recombinant IL5RA include pain at the injection site, redness and swelling at the injection site, cough, and sore throat. A small number of patients may experience allergic reactions or serious adverse reactions, so close monitoring of the patient's condition and signs is required when using.